Islet β-Cell Mass Preservation and Regeneration in Diabetes Mellitus: Four Factors with Potential Therapeutic Interest
- PMID: 22919462
- PMCID: PMC3420151
- DOI: 10.1155/2012/230870
Islet β-Cell Mass Preservation and Regeneration in Diabetes Mellitus: Four Factors with Potential Therapeutic Interest
Erratum in
-
Corrigendum to "Islet β-Cell Mass Preservation and Regeneration in Diabetes Mellitus: Four Factors with Potential Therapeutic Interest".J Transplant. 2019 Jun 2;2019:3281921. doi: 10.1155/2019/3281921. eCollection 2019. J Transplant. 2019. PMID: 31275625 Free PMC article.
Abstract
Islet β-cell replacement and regeneration are two promising approaches for the treatment of Type 1 Diabetes Mellitus. Indeed, the success of islet transplantation in normalizing blood glucose in diabetic patients has provided the proof of principle that cell replacement can be employed as a safe and efficacious treatment. Nonetheless, shortage of organ donors has hampered expansion of this approach. Alternative sources of insulin-producing cells are mandatory to fill this gap. Although great advances have been achieved in generating surrogate β-cells from stem cells, current protocols have yet to produce functionally mature insulin-secreting cells. Recently, the concept of islet regeneration in which new β-cells are formed from either residual β-cell proliferation or transdifferentiation of other endocrine islet cells has gained much interest as an attractive therapeutic alternative to restore β-cell mass. Complementary approaches to cell replacement and regeneration could aim at enhancing β-cell survival and function. Herein, we discuss the value of Hepatocyte Growth Factor (HGF), Glucose-Dependent Insulinotropic Peptide (GIP), Paired box gene 4 (Pax4) and Liver Receptor Homolog-1 (LRH-1) as key players for β-cell replacement and regeneration therapies. These factors convey β-cell protection and enhanced function as well as facilitating proliferation and transdifferentiation of other pancreatic cell types to β-cells, under stressful conditions.
Figures

Similar articles
-
Development of the endocrine pancreas and novel strategies for β-cell mass restoration and diabetes therapy.Braz J Med Biol Res. 2015 Sep;48(9):765-76. doi: 10.1590/1414-431X20154363. Epub 2015 Jul 10. Braz J Med Biol Res. 2015. PMID: 26176316 Free PMC article. Review.
-
A focus on the role of Pax4 in mature pancreatic islet beta-cell expansion and survival in health and disease.J Mol Endocrinol. 2008 Feb;40(2):37-45. doi: 10.1677/JME-07-0134. J Mol Endocrinol. 2008. PMID: 18234907 Review.
-
Pancreatic islet cell development and regeneration.Curr Opin Endocrinol Diabetes Obes. 2015 Aug;22(4):255-64. doi: 10.1097/MED.0000000000000174. Curr Opin Endocrinol Diabetes Obes. 2015. PMID: 26087337 Free PMC article. Review.
-
Transplantation of human dental pulp stem cells in streptozotocin-induced diabetic rats.Anat Sci Int. 2020 Sep;95(4):523-539. doi: 10.1007/s12565-020-00550-2. Epub 2020 May 31. Anat Sci Int. 2020. PMID: 32476103
-
Concise review: pancreas regeneration: recent advances and perspectives.Stem Cells Transl Med. 2012 Feb;1(2):150-9. doi: 10.5966/sctm.2011-0025. Epub 2012 Jan 26. Stem Cells Transl Med. 2012. PMID: 23197762 Free PMC article. Review.
Cited by
-
Antidiabetic actions of an estrogen receptor β selective agonist.Diabetes. 2013 Jun;62(6):2015-25. doi: 10.2337/db12-1562. Epub 2013 Jan 24. Diabetes. 2013. PMID: 23349481 Free PMC article.
-
Inhibition of the prostaglandin D2-GPR44/DP2 axis improves human islet survival and function.Diabetologia. 2020 Jul;63(7):1355-1367. doi: 10.1007/s00125-020-05138-z. Epub 2020 Apr 29. Diabetologia. 2020. PMID: 32350565 Free PMC article.
-
Transcriptional profiling reveals intrinsic mRNA alterations in multipotent mesenchymal stromal cells isolated from bone marrow of newly-diagnosed type 1 diabetes patients.Stem Cell Res Ther. 2016 Jul 12;7(1):92. doi: 10.1186/s13287-016-0351-y. Stem Cell Res Ther. 2016. PMID: 27406064 Free PMC article.
-
LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus.Nat Commun. 2018 Apr 16;9(1):1488. doi: 10.1038/s41467-018-03943-0. Nat Commun. 2018. PMID: 29662071 Free PMC article.
-
Exploring African Medicinal Plants for Potential Anti-Diabetic Compounds with the DIA-DB Inverse Virtual Screening Web Server.Molecules. 2019 May 24;24(10):2002. doi: 10.3390/molecules24102002. Molecules. 2019. PMID: 31137754 Free PMC article.
References
-
- Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53(4):614–623. - PubMed
-
- Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060–2069. - PubMed
-
- Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes. 2005;54(6):1755–1762. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous